Clinical Cancer Research, Vol 3, Issue 4 495-499, Copyright © 1997 by American Association for Cancer Research

ARTICLES

Serum sialyl lewis X-i antigen levels in non-small cell lung cancer: correlation with distant metastasis and survival

H Satoh, H Ishikawa, H Kamma, YT Yamashita, H Takahashi, M Ohtsuka and S Hasegawa
Department of Pulmonary Medicine, Institute of Clinical Medicine, University of Tsukuba, Tsukuba City,

To evaluate the correlation between serum levels of sialyl Lewis X-i antigen and distant metastasis and survival in patients with non-small cell lung cancer (NSCLC), we measured the serum levels of the tumor marker in 371 patients with untreated NSCLC. The sialyl Lewis X-i antigen level was measured using a RIA kit. In patients with adenocarcinoma or other NSCLC subtypes, there was a correlation between serum sialyl Lewis X-i antigen and stage of the disease (P = 0.0001 and P = 0.0015, respectively). Levels of the marker varied significantly depending on the number of metastatic organs in adenocarcinoma (P = 0.0089) and in other NSCLC subtypes (P = 0.002). Univariate analysis showed that survival of NSCLC patients with high (more than 100 units/ml) sialyl Lewis X-i antigen levels was significantly poorer than that of patients with low antigen levels (P = 0.0001). Multivariate analysis using Cox's proportional hazard model showed that high sialyl Lewis X-i antigen levels correlated significantly with poor survival (P = 0.004). Our data suggest that a high serum level of sialyl Lewis X-i antigen seems to be an indicator of the presence of metastasis and might indicate the need for a careful investigation of all putative metastatic sites. The serum levels of sialyl Lewis X-i antigen may reflect the extension of metastasis and would be helpful in considering treatment options.

This article has been cited by other articles:

				E. C. Adam, S. T. Holgate, and P. M. Lackie Epithelial repair is inhibited by an {alpha}1,6-fucose binding lectin Am J Physiol Lung Cell Mol Physiol, February 1, 2007; 292(2): L462 - L468. [Abstract] [Full Text] [PDF]

				J. Kurebayashi, T. Nomura, M. Hirono, S. Okubo, K. Udagawa, S. Shiiki, M. Ikeda, K. Nakashima, K. Tanaka, and H. Sonoo Combined Measurement of Serum Sialyl Lewis X with Serum CA15-3 in Breast Cancer Patients Jpn. J. Clin. Oncol., March 1, 2006; 36(3): 150 - 153. [Abstract] [Full Text] [PDF]

				E. Laack, H. Nikbakht, A. Peters, C. Kugler, Y. Jasiewicz, L. Edler, J. Brummer, U. Schumacher, and D. K. Hossfeld Expression of CEACAM1 in Adenocarcinoma of the Lung: A Factor of Independent Prognostic Significance J. Clin. Oncol., November 1, 2002; 20(21): 4279 - 4284. [Abstract] [Full Text] [PDF]

				H Satoh, H Ishikawa, Y T Yamashita, M Ohtsuka, and K Sekizawa Serum sialyl Lewis X-i antigen in lung adenocarcinoma and idiopathic pulmonary fibrosis Thorax, March 1, 2002; 57(3): 263 - 266. [Abstract] [Full Text] [PDF]

				S. M. Smorenburg and C. J. F. Van Noorden The Complex Effects of Heparins on Cancer Progression and Metastasis in Experimental Studies Pharmacol. Rev., March 1, 2001; 53(1): 93 - 106. [Abstract] [Full Text] [PDF]

				H. Satoh, H. Ishikawa, Y. T. Yamashita, Y.-C. Lee, S.-C. Chang, and J.-H. Chern Sialyl Lewis X-i Antigen in Pleural Effusion Chest, August 1, 1999; 116(2): 582 - 583. [Full Text] [PDF]